Market Overview

Eli Lilly Says Cialis Data Met Primary Endpoint

Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia. Cialis improved erectile dysfunction in those men who had both signs and symptoms of BPH and ED. The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin. This is the first international, placebo-controlled study evaluating Cialis in parallel with tamsulosin for signs and symptoms of BPH in the same population.

Posted-In: News FDA

 

Related Articles (LLY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional